Overview

Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt

Status:
Completed
Trial end date:
2019-06-30
Target enrollment:
0
Participant gender:
All
Summary
The overall prevalence of H. Pylori in the developing countries is 50.8%, with the highest one presented in Africa (79.1%). Hybrid therapy is supposed to be more effective as a first-line regimen for Helicobacter pylori infection in Egypt than the Reverse hybrid and non-bismuth Levofloxacin quadruple therapies. We are aiming here to compare the Hybrid, Reverse hybrid, and Levofloxacin quadruple therapies as first-line therapy, trying to reach the safest, cost-effective, and compliance-inducing regimen in Egypt. We will conduct a randomized controlled (interventional) study at Zagazig University Hospital, internal medicine department clinic, on 330 patients. 110 patients will be allocated to each regimen.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ayman Magd Eldin Mohammad Sadek
Treatments:
Levofloxacin
Ofloxacin
Criteria
Inclusion Criteria:

- Positive Helicobacter pylori antigen in the stool

- Treatment-naive

Exclusion Criteria:

- Previous treatment for Helicobacter pylori

- Drug hypersensitivity